Minerva Neurosciences Reports First Quarter 2015 Financial Results and Other Key Business Updates
May 07, 2015 08:00 ET
|
Minerva Neurosciences, Inc
MIN-101 Phase 2b trial for schizophrenia on track with enrollment underway; new regulatory approvals to conduct trials in Europe
MIN-117 Phase 2a study in Major Depressive Disorder (MDD) on track...
Minerva Neurosciences to Host First Quarter 2015 Financial Results Webcast and Conference Call
April 30, 2015 08:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., April 30, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Reports Fourth Quarter and Full Year 2014 Financial Results
March 26, 2015 16:01 ET
|
Minerva Neurosciences, Inc
- MIN-101 Phase 2b trial for schizophrenia on track -
- Phase 2a trial planned for MIN-202 in primary insomnia in mid-2015; Phase 1b in MDD patients also expected to begin in mid-2015 -
-...
Minerva Neurosciences to Host Fourth Quarter and Full Year 2014 Financial Results Webcast and Conference Call
March 19, 2015 17:39 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 19, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...
Minerva Neurosciences Completes Private Placement, Raises $31 Million
March 18, 2015 16:05 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 18, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced that it has closed the private placement announced on March 13, 2015. Investors in the...
Minerva Neurosciences Announces $31 Million Financing
March 13, 2015 09:17 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., March 13, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced that it will raise approximately $31 million of gross proceeds in a private placement...
Minerva Neurosciences Reports Positive Phase 1 Data With MIN-202, Selective Orexin-2 Antagonist for Treatment of Sleep Disorders Including Primary and Comorbid Insomnia
January 21, 2015 16:30 ET
|
Minerva Neurosciences, Inc
Preliminary results provide additional support for progression of MIN-202 into next stage of clinical development. Minerva developing MIN-202 in collaboration with Janssen.
WALTHAM, Mass., Jan....
Minerva Neurosciences Announces $15 Million Debt Facility With Oxford Finance LLC and Silicon Valley Bank
January 20, 2015 16:01 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Jan. 20, 2015 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV) today announced it has entered into a $15 million debt facility with Oxford Finance LLC (Oxford) and Silicon...
Minerva Neurosciences Reports Positive Data Showing an Analog of Minerva's MIN-301 Compound Improves Symptoms of Parkinson's Disease in Primates
January 05, 2015 16:01 ET
|
Minerva Neurosciences, Inc
Results provide further support for research involving use of neuregulin-1 compounds in treatment of Parkinson's and other neurodegenerative disorders
WALTHAM, Mass., Jan. 5, 2015 (GLOBE NEWSWIRE)...
Minerva Neurosciences Announces Completion of Development and Final Selection of Once-Daily Dose Formulation of MIN-101 for Its Schizophrenia Program
December 03, 2014 07:00 ET
|
Minerva Neurosciences, Inc
WALTHAM, Mass., Dec. 3, 2014 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a clinical-stage biopharmaceutical company focused on the development of innovative therapies to treat...